Research programme: arrhythmia therapeutics - AstraZenecaAlternative Names: AZD 3118
Latest Information Update: 17 Dec 2007
At a glance
- Originator AstraZeneca
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Arrhythmias
Most Recent Events
- 17 Dec 2007 Discontinued - Preclinical for Arrhythmias (unspecified route)
- 31 Jul 2007 Preclinical trials in Arrhythmias (unspecified route)